LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

TransMedics Group Inc

Gesloten

SectorGezondheidszorg

114.92 -0.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

110.43

Max

115.8

Belangrijke statistieken

By Trading Economics

Inkomsten

-11M

24M

Verkoop

-14M

144M

K/W

Sectorgemiddelde

47.996

105.69

Winstmarge

16.909

Werknemers

728

EBITDA

-13M

33M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+24.34% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-333M

4.2B

Vorige openingsprijs

115.64

Vorige sluitingsprijs

114.92

Nieuwssentiment

By Acuity

50%

50%

185 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

TransMedics Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Peer Vergelijking

Prijswijziging

TransMedics Group Inc Prognose

Koersdoel

By TipRanks

24.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 143.67 USD  24.34%

Hoogste 170 USD

Laagste 115 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor TransMedics Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

8

Buy

2

Hold

0

Sell

Technische score

By Trading Central

92.43 / 94.18Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

185 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat